<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34811773</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>94</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Seroprevalence of coxsackievirus A21 neutralizing antibodies in Yamagata, Japan, between 1976 and 2019; coxsackievirus A21 has rarely affected young children.</ArticleTitle><Pagination><StartPage>2877</StartPage><EndPage>2881</EndPage><MedlinePgn>2877-2881</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.27470</ELocationID><Abstract><AbstractText>Although coxsackievirus A21 (CV-A21) has been associated with an acute respiratory infection (ARI) as well as poliomyelitis-like paralysis, reports of CV-A21 detection have been quite limited both globally and in Japan. CV-A21 strains were isolated from five sporadic pediatric cases with ARI in 2019 in Yamagata, Japan. Neutralizing antibodies (NT Abs) were then measured against CV-A21 using sera collected in 1976, 1985, 1999, 2009, and 2019 in Yamagata, to clarify the longitudinal epidemiology of CV-A21. The total Ab-positive rate in each year was 15.2% (35/233), 10.7% (30/281), 14.3% (28/196), 3.1% (7/236), and 1.3% (3/226), respectively. Ab-positive rates generally increased with age, especially between 1976 and 1999. Among the total Ab-positive cases, the Ab titers were relatively low; 50 cases belonged to the 1:8-1:16, 40 to 1:32-1:64, 12 to 1:128-1:256, and 1 to 1:1024&lt; groups, respectively. No Ab-positive cases under the age of 10 were observed in any of the years analyzed. In conclusion, this study and previous works suggested that CV-A21 is a unique enterovirus, which is not transmitted readily among young children but causes sporadic ARI cases mainly among those ≥15 years of age in the community.</AbstractText><CopyrightInformation>© 2021 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Waka</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Yamagata Prefectural Institute of Public Health, Yamagata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komabayashi</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-0900-8845</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, Yamagata Prefectural Institute of Public Health, Yamagata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Yoko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Yamagata Prefectural Institute of Public Health, Yamagata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Yoko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Yamagata Prefectural Institute of Public Health, Yamagata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itagaki</LastName><ForeName>Tsutomu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Yamanobe Pediatric Clinic, Yamagata, Yamanobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizuta</LastName><ForeName>Katsumi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Yamagata Prefectural Institute of Public Health, Yamagata, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050504" MajorTopicYN="Y">Oncolytic Viruses</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="Y">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">coxsackieivrus A21</Keyword><Keyword MajorTopicYN="N">seroepidemiology</Keyword><Keyword MajorTopicYN="N">seroprevalence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34811773</ArticleId><ArticleId IdType="doi">10.1002/jmv.27470</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Cherry J, Krogstad P. Enteroviruses, parechoviruses, and Saffold viruses. In: Cherry JD, Harrison GJ, Kaplan SL, Steinbach WJ, Hotez PJ, eds. Feigin and Cherry's Textbook of Pediatric Infectious Diseases. 8th ed. Elsvier; 2019:1499-1544.</Citation></Reference><Reference><Citation>Lennette EH, Fox VL, Schmidt NJ, Culver JO. The Coe virus: an apparently new virus recovered from patients with mild respiratory disease. Am J Hyg. 1958;68:272-287.</Citation></Reference><Reference><Citation>Pereira MS, Pereira HG, Brazil M. Coe virus properties and prevalence in Great Britain. Lancet. 1959;2:539-541.</Citation></Reference><Reference><Citation>McDonald JC, Miller DL, Zuckerman AJ, Pereira MS. Coe (Coxsackie A 21) virus, para-influenza virus and other respiratory virus infections in the R.A.F., 1958-60. J Hyg (Lond). 1962;60:235-248.</Citation></Reference><Reference><Citation>Fukumi H, Nishikawa F, Sonoguchi T, Shimizu T. Further studies on serological epidemiology of Coe virus infection. Jpn J Med Sci Biol. 1962;15:145-151.</Citation></Reference><Reference><Citation>Johnson KM, Bloom HH, Chanock RM, Mufson MA, Knight V. Acute respiratory diseases of viral etiology. VI. The newer enteroviruses. Am J Public Health Nations Health. 1962;52:933-940.</Citation></Reference><Reference><Citation>Spickard A, Evans H, Knight V, Johnson K. Acute respiratory disease in normal volunteers associated with Coxsackie A-21 viral infection. III. Response to nasopharyngeal and enteric inoculation. J Clin Invest. 1963;42:840-852.</Citation></Reference><Reference><Citation>Murao M, Matsunaga Y, Momose T. A cluster of coxsackieivrus A21 in Saitama. Japan. Infect Agents Surveillance Rep. 1986;82:232-246.</Citation></Reference><Reference><Citation>Rakoto-Andrianarivelo M, Rousset D, Razafindratsimandresy R, et al. High frequency of human enterovirus species C circulation in Madagascar. J.Clin.Microbiol. 2005;43:242-249.</Citation></Reference><Reference><Citation>Khetsuriani N, Lamonte-Fowlkes A, Oberst S, Pallansch MA, Centers for Disease Control and Prevention. Enterovirus surveillance-United States, 1970-2005. MMWR Surveill Summ. 2006;55:1-20.</Citation></Reference><Reference><Citation>Xiang Z, Gonzalez R, Wang Z, et al. Coxsackievirus A21, enterovirus 68, and acute respiratory tract infection, China. Emerg Infect Dis. 2012;18:821-824.</Citation></Reference><Reference><Citation>Puenpa J, Mauleekoonphairoj J, Linsuwanon P, et al. Prevalence and characterization of enterovirus infections among pediatric patients with hand foot mouth disease, herpangina and influenza like illness in Thailand, 2012. PLOS One. 2014;9:e98888.</Citation></Reference><Reference><Citation>Wang S, Xu M, Lin X, et al. Molecular characterization of coxsackievirus A21 in Shandong, China. Arch Virol. 2016;161:437-444.</Citation></Reference><Reference><Citation>Zou L, Yi L, Song Y, et al. A cluster of coxsackievirus A21 associated acute respiratory illness: the evidence of efficient transmission of CVA21. Arch Virol. 2017;162:1057-1059.</Citation></Reference><Reference><Citation>Hang J, Vento TJ, Norby EA, et al. Adenovirus type 4 respiratory infections with a concurrent outbreak of coxsackievirus A21 among United States Army Basic Trainees, a retrospective viral etiology study using next-generation sequencing. J Med Virol. 2017;89:1387-1394.</Citation></Reference><Reference><Citation>Linster M, Donato C, Mah MG, et al. Genetic diversity of respiratory enteroviruses and rhinoviruses in febrile adults, Singapore, 2007-2013. Influenza Other Respi viruses. 2019;14:67-71.</Citation></Reference><Reference><Citation>Ikeda T, Aoki Y, Komabayashi K, Itagaki T, Mizuta K. Isolation of coxsackievirus A21 from patients with acute respiratory infection in Yamagata, Japan in 2019. Jpn J Infect Dis. 2021;74:172-174.</Citation></Reference><Reference><Citation>National Epidemiological Surveillance of Infectious Diseases, Japan (NESID) 2021. Accessed June 29, 2021. https://nesid4g.mhlw.hq.admix.go.jp/GKWeb/GKMainServlet</Citation></Reference><Reference><Citation>Mizuta K, Tanaka W, Komabayashi K, et al. Longitudinal epidemiology of viral infectious diseases combining virus isolation, antigenic analysis, and phylogenetic analysis as well as seroepidemiology in Yamagata, Japan between 1999 and 2018. Jpn J Infect Dis. 2019;72:211-223.</Citation></Reference><Reference><Citation>Mizuta K, Komabayashi K, Aoki Y, Itagaki T, Ikeda T. Seroprevalence of parechovirus A1, A3 and A4 antibodies in Yamagata, Japan, between 1976 and 2017. J Med Microbiol. 2020;69:1381-1387.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>